Company profile: ILiAD Biotechnologies
1.1 - Company Overview
Company description
- Provider of clinical-stage biotech focused on preventing and treating Bordetella pertussis disease, offering BPZE1, a live attenuated pertussis vaccine candidate; the B-Tech program and vector platform for therapeutic development and immune induction; vaccine candidates incl. IB-002A; B. pertussis disease research; and BioLyo services for live biological manufacturing process development.
Products and services
- BPZE1 Vaccine: A live-attenuated vaccine candidate engineered to prevent whooping cough by eliminating, attenuating, or inactivating three distinct Bordetella pertussis toxins
- B-Tech Vector Platform: A vector-based delivery system that induces immune responses against pathogens and immuno-oncology targets, demonstrated in pre-clinical studies
- Vaccine Candidates: Platform-derived new clinical candidates, including IB-002A, architected to optimize therapeutic allergy effects and expand development from the B-Tech platform
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ILiAD Biotechnologies
AiCuris
HQ: Germany
Website
- Description: Provider of resistance breaking antiviral and antibacterial therapeutics targeting CMV, HSV, HIV, hepatitis B and C, and multi-resistant bacteria; offerings include PREVYMIS for CMV prevention in adult CMV-seropositive allogeneic stem cell or kidney transplant recipients, pritelivir (phase 3) for acyclovir-resistant HSV, AIC468 (preclinical) for BK virus, adenovirus treatment programs, and the AiCubator for early-stage research on viral infections in immunocompromised patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AiCuris company profile →
Coulter Pharmaceutical
HQ: United States
Website
- Description: Provider of immunotherapeutics aimed at treating and preventing autoimmune diseases, cancer, and infectious diseases by understanding and directing the immune system; conducted preclinical development programs including the BEXXAR therapy and MELACINE vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coulter Pharmaceutical company profile →
Lumen Bioscience
HQ: United States
Website
- Description: Provider of biologic drug and vaccine development and manufacturing, leveraging a platform for rapid, cost-effective production. Pipeline includes biologic cocktails for C. difficile colitis, Covid-19 GI infection, and inflammatory bowel disease, a preclinical cardiometabolic program with Novo Nordisk, and a Phase 2 product candidate for traveler’s diarrhea backed by CARB-X and the Bill & Melinda Gates Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumen Bioscience company profile →
Fluoresentric
HQ: United States
Website
- Description: Provider of assay design, optimization, and custom manufacturing services for the healthcare and biotechnology sector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluoresentric company profile →
Iterum Therapeutics
HQ: Ireland
Website
- Description: Provider of clinical-stage anti-infectives targeting multi-drug resistant pathogens. Offers sulopenem, an oral and IV penem antibiotic with broad-spectrum activity against multi-drug resistant gram-negative infections in hospital and community settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iterum Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ILiAD Biotechnologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ILiAD Biotechnologies
2.2 - Growth funds investing in similar companies to ILiAD Biotechnologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ILiAD Biotechnologies
4.2 - Public trading comparable groups for ILiAD Biotechnologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →